Announcing Partnership with BIO

Vending Machine has partnered with BIO, described as "a new financial layer for decentralised science." Through this collaboration, Vending Machine will provide token design, economic simulations, and protocol parameterizations to BIO.

The Scope of the BIO Relationship

1. Parameterising Genesis Auction 2: Optimizing token allocation and asset weightings to support protocol longevity and community engagement.
2. Designing the BIO token system functionality: Integrating the BIO token within the protocol, creating user workflows, and establishing functionality across the decentralized science ecosystem.
3. Supporting the economic framework for newly incubated bioDAOs: Building baseline economic frameworks for new bioDAOs to reduce initial design overhead, freeing organizations to focus on scientific work.
4. BIO economic simulations and parameterisations: Running protocol simulations and refining parameters for "long-term success and sustainability."

Why BIO?

Bottom-up Funding, Strong Incentives, and Empowering Patients

The partnership addresses a fundamental problem in pharmaceutical research: the traditional funding model is "top-down, profit-driven, and often detached from patients and their actual needs." Many niche patient communities lack treatment options and viable research funding.

DeSci (Decentralized Science) mirrors DeFi's approach to finance by enabling "patients to fund research that the conventional Big Pharma model has neglected." Communities with shared health concerns can pool resources to directly support scientific research targeting their conditions.

BIO aims to simplify bioDAO creation for scientific funding. Vending Machine's role focuses on eliminating economic complexity so researchers and communities can concentrate on the science itself. The partnership will share updates across these four critical initiatives, building "a robust economic network that is ultimately geared towards accelerating scientific discovery and breakthrough medications."